Updates from the 2025 American Diabetes Association guidelines on standards of medical care in diabetes

Abstract

Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity. In fact, cardiovascular disease is the leading cause of death in patients with diabetes mainly from heart failure or myocardial infarction. The newer therapeutic agents in diabetes have positive impact on both cardiovascular and renal outcomes. Thus, the American Diabetes Association (ADA)’s annual update on the Standards of Medical Care in Diabetes is an important resource for all caregivers involved in diabetes management as it incorporates the latest scientific research, clinical evidence, and emerging technologies in diabetes management. The 2025 guidelines present significant updates that reflect a deeper understanding of diabetes management, emphasizing expanded usage of technologies such as continuous glucose monitoring, personalized pharmacological approaches, and lifestyle interventions. This commentary provides an analysis of the key updates in the 2025 ADA guidelines exploring implications for clinical practice, laboratory assessments, and public health policy. Where relevant, comparisons to the 2024 version will be made.

Keywords

American Diabetes Association / continuous glucose monitoring / diabetes / diabetic kidney disease / glucagon-like peptide-1 receptor agonists / HbA1c / sodium-glucose cotransporter 2 inhibitors / type 2 diabetes mellitus

References

[1] Global: Diabetes global report 2000-2050 [Internet]. International Diabetes Federation; c2025 [cited 2025 Mar 20]. Available from: https://diabetesatlas.org/data/

[2] Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44: 4043-140.

[3] Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Ann Intern Med. 2023; 176: 381-7.

[4] Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm-2023 Update. Endocr Pract. 2023; 29: 305-40.

[5] American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S20-42.

[6] American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S27-49.

[7] American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S50-8.

[8] Vedantam D, Poman DS, Motwani L, Asif N, Patel A, Anne KK. Stress-Induced Hyperglycemia: Consequences and Management. Cureus. 2022; 14: e26714.

[9] Mason IC, Qian J, Adler GK, Scheer FAJL. Impact of circadian disruption on glucose metabolism: implications for type 2 diabetes. Diabetologia. 2020; 63: 462-72.

[10] Sacks DB, Kirkman MS, Little RR. Point-of-Care HbA_1c in Clinical Practice: Caveats and Considerations for Optimal Use. Diabetes Care. 2024; 47: 1104-10.

[11] Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. Clin Gastroenterol Hepatol. 2024; 22: 1565-74.

[12] Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TT, et al. GLP-1 receptor agonists’ impact on cardiorenal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024; 15: 5912.

[13] Loh WJ. Overview of diabetes agents in cardiovascular disease: it takes an orchestra to play Tchaikovsky in symphony. Curr Opin Endocrinol Diabetes Obes. 2025; 32: 3-11.

[14] American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S181-206.

[15] Trevella P, Ekinci EI, MacIsaac RJ. Potential kidney protective effects of glucagon-like peptide-1 receptor agonists. Nephrology (Carlton). 2024; 29: 457-69.

[16] American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S59-85.

[17] American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S207-38.

[18] American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S321-34.

[19] American Diabetes Association Professional Practice Committee. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S86-127.

[20] American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S239-51.

[21] American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S145-57.

[22] Malik VS, Hu FB. The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases. Nat Rev Endocrinol. 2022; 18: 205- 18.

[23] Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients. 2018; 10: 423.

[24] Akturk HK, Snell-Bergeon J, Kinney GL, Champakanath A, Monte A, Shah VN. Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes. Diabetes Care. 2022; 45: 481-3.

[25] American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S146-66.

[26] Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ. Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration. Diabetes Care. 2023; 46: 854-63.

[27] Considine EG, Sherr JL. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technol Ther. 2024; 26: 53-65.

[28] Pang S, Li X. Early use of SGLT2 inhibitors reduces the progression of diabetic kidney disease: a retrospective cohort study. Am J Transl Res. 2024; 16: 4967-78.

[29] Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024; 404: 773-86.

[30] Tiwari D, Aw TC. Emerging Role of Natriuretic Peptides in Diabetes Care: A Brief Review of Pertinent Recent Literature. Diagnostics (Basel). 2024; 14: 2251.

[31] Ng SM, Wright NP, Yardley D, Campbell F, Randell T, Trevelyan N, et al. Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes. BMC Med. 2024; 22: 175.

[32] Iacobucci G. Diabetes: Global treatment gap is widening, study finds. BMJ. 2024; 387: q2515.

[33] American Diabetes Association Professional Practice Committee. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S14-26.